Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Clear cell papillary RCC distinguished by unique staining pattern

Wang Y et al. Annals of Diagnostic Pathology 36: 2018; 1-4. https://doi.org/10.1016/j.anndiagpath.2018.06.007

Key clinical point: Clear cell papillary renal cell carcinoma (ccpRCC) is a recently recognized subtype of renal cell carcinoma with a unique staining pattern that can be used to distinguish this cancer. Further, vitamin D receptor-positive expression suggests that ccpRCC originates from the precursor epithelium of the distal nephron.

Major finding: Histopathologically, all 26 cases of ccpRCC exhibited a tubular and papillary architecture, covered by tumor cells with clear cytoplasm. Immunohistochemistry showed intermediate (5/26, 19%) to diffuse (21/26, 81%) and moderate (2/26, 8%) to strong (24/26, 92%) membranous staining for vitamin D receptor. All cases (26/26, 100%) were diffuse with strong cytoplasmic and fibrillar staining for cytokeratin 7 (CK7), but negative for α-methylacyl-CoA-racemase (AMACR). Each case showed diffuse (26/26, 100%) and moderate (4/26, 15%) to strong (22/26, 85%) membranous staining for carbonic anhydrase IX (CA IX). In addition, the majority of cases were negative for cluster of differentiation 10 (CD10) (20/26, 77%) and renal cell carcinoma maker (RCC-Ma) (24/26, 92%).

Study details: The clinicopathological and immunohistochemical features of ccpRCC were examined in 26 patients, mean age 53 years (range 36–74 years), with a mean tumor size of 2.5 cm (range 0.5 to 6.5 cm).

Disclosures: The authors had no relevant financial disclosures.

Source: Wang Y et al. Annals of Diagnostic Pathology 36: 2018; 1-4. https://doi.org/10.1016/j.anndiagpath.2018.06.007

Citation:

Wang Y et al. Annals of Diagnostic Pathology 36: 2018; 1-4. https://doi.org/10.1016/j.anndiagpath.2018.06.007

This Week's Must Reads

Perioperative radiation therapy underused in elderly patients with soft tissue sarcomas, Venigalla S et al. Intl J Rad Oncology*Biology*Physics; September (102) 2018: 155-165. https://doi.org/10.1016/j.ijrobp.2018.05.019

Age, R0 resection, and adjuvant radiotherapy boost outcomes in myxofibrosarcoma, Boughzala-Bennadji R et al. Intl J Rad Oncology*Biology*Physics; October (102) 2018: 399-406. https://doi.org/10.1016/j.ijrobp.2018.05.055

Tumor size, invasion beyond subcutaneous fat predict adverse outcomes in undifferentiated pleomorphic sarcoma, Winchester D et al. J Am Acad Dermatol. Available online 19 May 2018 https://doi.org/10.1016/j.jaad.2018.05.022

High recurrence rate after pancreaticoduodenectomy for primary retroperitoneal sarcoma, Tseng W et al. European Journal of Surgical Oncology 2018 (44): June; 810-815.

Nivolumab, pembrolizumab successfully used in Kaposi sarcoma, Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.

Must Reads in Renal Cell Carcinoma

In mRCC: Sunitinib alone not inferior to nephrectomy-sunitinib, Méjean A et al. N Engl J Med. 2018 Aug 2. doi: 10.1056/NEJMoa1803675.

Proactive management eases side effects of sunitinib treatment in RCC, Staehler M et al. Ann Oncol. 2018 Aug 23. doi: 10.1093/annonc/mdy329

Red cell distribution width might predict cancer-specific survival in RCC , Życzkowski M et al. Clinical Genitourinary Cancer 2018 June (16), e677-e683. https://doi.org/10.1016/j.clgc.2017.12.003

mRCC: Patients survive longer at high-volume centers, Joshi SS et al. Euro Urol. 2018 Sep;74[3]:387-93.

High PD1 mRNA levels tied to anti-PD1 monotherapy response, Paré L et al. Ann Oncol. 2018 Aug 27. doi: 10.1093/annonc/mdy335.